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Clinical and Laboratory Features of Mycobacterium porcinum†
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Recent molecular studies have shown Mycobacterium porcinum, recovered from cases of lymphadenitis in
swine, to have complete 16S rDNA sequence identity and >70% DNA-DNA homology with human isolates
within the M. fortuitum third biovariant complex. We identified 67 clinical and two environmental isolates of
the M. fortuitum third biovariant sorbitol-negative group, of which 48 (70%) had the same PCR restriction
enzyme analysis (PRA) profile as the hsp65 gene of M. porcinum (ATCC 33776T) and were studied in more
detail. Most U.S. patient isolates were from Texas (44%), Florida (19%), or other southern coastal states (15%).
Clinical infections included wound infections (62%), central catheter infections and/or bacteremia (16%), and
possible pneumonitis (18%). Sequencing of the 16S rRNA gene (1,463 bp) showed 100% identity with M.
porcinum ATCC 33776T. Sequencing of 441 bp of the hsp65 gene showed four sequevars that differed by 2 to 3
bp from the porcine strains. Clinical isolates were positive for arylsulfatase activity at 3 days, nitrate, iron
uptake, D-mannitol, i-myo-inositol, and catalase at 68°C. They were negative for L-rhamnose and D-glucitol
(sorbitol). Clinical isolates were susceptible to ciprofloxacin, sulfamethoxazole, and linezolid and susceptible
or intermediate to cefoxitin, clarithromycin, imipenem, and amikacin. M. porcinum ATCC 33776T gave similar
results except for being nitrate negative. These studies showed almost complete phenotypic and molecular
identity between clinical isolates of the M. fortuitum third biovariant D-sorbitol-negative group and porcine
strains of M. porcinum and confirmed that they belong to the same species. Identification of M. porcinum
presently requires hsp65 gene PRA or 16S rRNA or hsp65 gene sequencing.
The rapidly growing mycobacterial species Mycobacterium
porcinum was described in 1983 by Tsukamura et al. as a
causative agent of submandibular lymphadenitis in swine (23).
Tsukamura et al. characterized these strains as being similar to
M. fortuitum but differing from this species by being D-mannitol
and i-myo-inositol positive, nitrate negative, and succinamidase positive and utilizing benzoate as a sole source of carbon
in the presence of ammoniacal nitrogen. Until recently, no
isolation of this species had been reported since that report.
Bönicke studied isolates previously identified as M. fortuitum
and placed them into three subgroups (1). Subgroup A was
negative for D-mannitol and i-myo-inositol and now is recog-

nized as M. fortuitum. Subgroup B was positive for D-mannitol
but negative for i-myo-inositol and is now recognized as M. peregrinum. Subgroup C was positive for mannitol and inositol, and
its taxonomic status has taken much longer to establish and is still
evolving. A study by Wallace et al. in 1991 showed this subgroup
to consist of two major groups. One group was D-sorbitol positive,
had low semiquantitative catalase, and was pipemidic acid resistant, and MICs of cefoxitin (27) and clarithromycin (4) were high
for members of the group. ␤-Lactamase patterns on polyacrylamide gels following isoelectric focusing (IEF) had previously
showed these isolates to have primarily a single enzyme pattern
(28). These isolates were named the M. fortuitum third biovariant
complex D-sorbitol-positive group, and ATCC 49403 was chosen
as the reference strain (27).
Subsequent 16S rRNA gene sequencing showed these isolates to have a unique hypervariable A region (11, 19) and an
880-bp sequence of ATCC 49403 to differ by 6 to 15 bp from
previously recognized species within the M. fortuitum group
(11). To date, three species are recognized within this D-sorbitol-positive group based on 16S rDNA complete sequencing
and DNA-DNA homology studies: M. mageritense (7, 26), M.
houstonense (of which ATCC 49403 is the proposed type
strain), and M. brisbanense (16).

* Corresponding author. Mailing address: Department of Microbiology, The University of Texas Health Center, 11937 U.S. Highway
271, Tyler, TX 75708. Phone: (903) 877-7680. Fax: (903) 877-7652.
E-mail: richard.wallace@uthct.edu.
† This paper is dedicated to the three coauthors Vella Silcox, Zeta
Blacklock, and Michio Tsukamura, early investigators who contributed
greatly to the present study but who retired before the present taxonomic status of isolates of the third biovariant complex was established. Both Zeta Blacklock and Michio Tsukamura passed away prior
to submission of this study.
‡ Present address: Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, MO 63140.
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MATERIALS AND METHODS
Mycobacterial isolates. Clinical isolates of the M. fortuitum third biovariant
sorbitol-negative group submitted to the Mycobacteria/Nocardia Laboratory at
The University of Texas Health Center at Tyler for identification or susceptibility
testing and the type strain of M. porcinum (ATCC 33776) were subjected to PCR
restriction enzyme analysis (PRA) of the Telenti sequence of the hsp65 gene (20,
22). Two clinical isolates had previously been submitted to the American Type
Culture Collection (ATCC; Manassas, Va.) and numbered as ATCC 49939 and
ATCC BAA-328. Information on clinical histories, specimen type, and geographic location was obtained at the time of isolate submission. Chart reviews
and informed consent were not obtained. Most clinical information was obtained
before current Health Information Patient Protection Agency guidelines were in
place. Care was taken not to utilize any specific patient identifiers and to protect
patient confidentiality.
Sixty-seven clinical and two environmental isolates of the M. fortuitum third
biovariant D-sorbitol-negative group were subjected to PRA. Of these, 46 clinical
and two environmental isolates (48 isolates or 70%) had a PRA pattern identical
to that of M. porcinum ATCC 33776T and were studied for clinical site and
geographical source. Among the 45 patient isolates for which culture sites were
known, 8 (18%) were respiratory; 7 (16%) were from central catheter-related
infections and/or bacteremia and included five known cases of bacteremia; 28
(62%) were from postsurgical (7 cases), posttraumatic (12 cases), or unknown

types (9 cases) of wound infections; 1 (2%) was from an infected lymph node;
and 1 (2%) was from urine. Seven cases involved known associated osteomyelitis
(Table 1). Two environmental isolates were recovered from tap water as part of
an investigation of catheter-related infections in a bone marrow transplant unit
in Texas (8). When treatment of the patients’ infections was based on susceptibility results, with appropriate surgical intervention, all 12 cases with detailed
follow-up resulted in clinical resolution.
The 46 isolates for which geographical information was provided were from 16
states and Queensland, Australia. Multiple isolates were obtained from Texas
(19 isolates or 41%), Florida (9 isolates or 20%), North Carolina (3 isolates), and
Australia (2 isolates). All but eight isolates from the United States (36 of 44
isolates or 82%) were from southern coastal states.
The ATCC reference strains included M. porcinum ATCC 33776T and ATCC
33775, M. peregrinum type I ATCC 14467T, M. senegalense ATCC 35796T and
ATCC 13781, M. neworleansense ATCC 49404T, M. houstonense ATCC 49403T,
and M. septicum ATCC 700731T.
Growth and biochemical characteristics. Isolates were examined for colony
morphology on Mueller-Hinton agar, pigmentation after 1 and 2 weeks (early
and late), growth within 7 days on Trypticase soy agar and Middlebrook 7H11
agar at 30°C, and carbohydrate utilization of D-mannitol, i-myo-inositol, and
D-glucitol (sorbitol) (2, 10, 18, 24, 26, 31). Selected isolates were tested for
growth at 35 and 45°C; arylsulfatase activity at 3 days; catalase activity at 68°C;
semiquantitative catalase activity; nitrate reductase activity; iron uptake; growth
on MacConkey agar; utilization of L-rhamnose, D-trehalose, citrate, benzoate,
and acetamide as sole carbon sources (2, 10, 18, 24, 26, 31); and IEF patterns of
␤-lactamase by using polyacrylamide gels (32). Additionally, most isolates were
tested for inhibition by commercial disks of polymyxin B, cephalothin, and
kanamycin using agar disk diffusion on Mueller-Hinton agar (Table 2) (26).
Results for some isolates have previously been published as part of earlier
taxonomic studies (27, 32).
HPLC. Mycolic acids were prepared, esterified, and then subjected to fluorescence detection high-performance liquid chromatography (FL-HPLC) as previously described (2, 26, 31). HPLC reference strains included M. fortuitum ATCC
6841T, M. peregrinum ATCC 14467T, M. intracellulare ATCC 13950T, and M.
neworleansense ATCC 49404T.
Susceptibility testing. Susceptibility testing for 11 antimicrobial agents was
performed using the broth microdilution method (3, 21) and the recently approved NCCLS standard M24-A (13). Drugs tested were amikacin, tobramycin,
cefoxitin, imipenem, doxycycline, ciprofloxacin, gatifloxacin, levofloxacin, clarithromycin, linezolid, and sulfamethoxazole. Control strains included Staphylococcus aureus ATCC 29213 and M. peregrinum ATCC 700686 (13) (Table 3).
Thirty-nine of the 48 isolates (including the two ATCC reference strains) recovered from all time periods were tested against eight of the drugs (the remaining
nine isolates had been submitted only for identification, and drug susceptibilities
had not been determined), while a smaller number of only recent isolates were
tested against three drugs only recently made available (levofloxacin, gatifloxacin, and linezolid).
PRA. Genomic DNA from all isolates was subjected to PCR amplification of
the 441-bp Telenti sequence of the hsp65 gene (20, 22). The PCR product was
digested with BstEII and HaeIII, and the DNA restriction fragments were
separated using 3% metaphor agarose gels. Selected strains were also cut with
BsaHI. Fragment sizes (in base pairs) were estimated using a computerized Bio
Image System (Millipore, Bedford, Mass.).
16S rRNA gene sequencing. Selected isolates of the third biovariant complex
sorbitol-negative group and the M. porcinum type strain underwent sequencing
of the first 500 bp using the MicroSeq 500 16S rDNA Bacterial Sequencing Kit
(Applied Biosystems, Foster City, Calif.) at Mayo Clinic (9, 14). More complete
16S rRNA gene sequencing was also performed on select isolates using an
in-house sequencing protocol (25). This included bases 27 to 1490 (total, 1,463
bases) spanning both hypervariable regions A and B.
hsp65 partial gene sequencing. Selected isolates of the third biovariant complex sorbitol-negative group, M. porcinum ATCC 33776T, and M. porcinum
ATCC 33775 were chosen for sequencing of the 441-bp Telenti fragment of the
hsp65 gene (25). Sequencing of the PCR product obtained using the previously
described protocol (22) was performed using the same PCR primers (TB11 and
TB12) in a forward and reverse sequencing reaction according to the manufacturer’s instructions (Applied Biosystems). Sequence editing and phylogenetic
analyses by ClustalV (neighbor-joining method) were performed using the Seqman and Megalign components of Lasergene 5 (DNASTAR).
Nucleotide sequence accession numbers. Examples of the five sequevars of
hsp65 seen with M. porcinum have been deposited in GenBank as sequevar 1,
accession number AY496137 (ATCC 33776T); sequevar 2, accession number
AY496138 (ATCC BAA-328); sequevar 3, accession number AY496139 (Mf-
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The other major subgroup identified by Wallace et al. (27)
within Bonicke’s subgroup C (1) was D-sorbitol negative, had a
high (height of column of bubbles, ⬎100 mm) semiquantitative
catalase, was pipemidic acid susceptible, and was susceptible or
intermediate to cefoxitin and clarithromycin (4). This group
was named the M. fortuitum third biovariant complex D-sorbitol-negative group (27). Subsequent 16S rRNA gene sequencing showed all studied isolates to have an identical but unique
hypervariable A region (19). However, IEF studies of the
␤-lactamase from this group showed a surprising multitude of
enzyme patterns, suggesting that multiple taxa or species might
be present (32). The first species within this group to be identified was M. septicum (17). Only one strain of M. septicum has
been reported (17), and the majority of isolates of this group
were still to be identified to the species level.
This quickly changed when recent molecular studies showed
complete sequence identity between the 16S rRNA gene of M.
porcinum and some of the unnamed isolates of the M. fortuitum
third biovariant D-sorbitol-negative group (16, 25). Schinsky et
al. (16) found four human strains of the third biovariant Dsorbitol-negative group to have 100% sequence identity over
1,401 bp with the M. porcinum type strain, ATCC 33776. This
latter strain had 91% homology with DNA-DNA comparison
to ATCC BAA-328, which is a typical clinical strain of the third
biovariant D-sorbitol-negative group.
The original description of M. porcinum in 1983 by Tsukamura et al. (23) appears very similar to that of isolates within
Bonicke’s subgroup C (1) that presently contain the M. fortuitum third biovariant, but phenotypic and molecular comparison of these two groups was not done when M. porcinum was
first described (23). Some phenotypic and drug susceptibility
studies on 13 clinical strains of M. porcinum were recently
reported (16). We compared the type strain of M. porcinum
and select clinical isolates of the third biovariant D-sorbitolnegative group, including the 13 clinical isolates in the recent
taxonomy study (16), by a number of phenotypic and molecular
methods to provide additional comparative data for these two
taxa. (This work was presented in part as an abstract to the
American Society for Microbiology meeting in Washington,
D.C., in May 2003.)
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TABLE 1. Clinical and geographic locations of the 46 clinical and 2 reference isolates of the selected PRA group of the sorbitol-negative
third biovariant complex
Isolate type and name

Source

Geographic
location

Clinical disease

Sputum
Lung biopsy
Sputum
Sputum
Sputum
Sputum
Sputum
Sputum

Florida
Georgia
Texas
Texas
Australia
Virginia
Texas
Illinois

Unknown
Pneumonia
Unknown
Pneumonia
Unknown
Unknown
Bronchiectasis
Cystic bronchiectasis

Catheter or blood related
Mf-115
Mf-533
Mf-537
Mf-1581
Mf-1600
Mf-1847
Mf-2190

Blood
Abdominal wall drainage
Blood
Blood
Not specified
Catheter site
Blood

Florida
Texas
Texas
Texas
Iowa
Washington
North Carolina

Catheter sepsis
Peritoneal catheter exit site infection
Catheter sepsis
Catheter sepsis
Catheter sepsis
Infected catheter site
Hemodialysis related

Leg amputation wound
Open ankle fracture
Traumatic knee wound
Surgical abdominal wound
Traumatic foot wound
Surgical chest wound
Traumatic leg lesion
Open ankle fracture
Sinus, left leg
Surgical back wound
Traumatic thigh wound
Abdominal wound
Leg wound
Spinal cord stimulator
pocket
Arm bone tissue
Leg tissue
Traumatic arm wound
Base of toe
Breast
Breast needle aspiration
Traumatic foot wound
Hand tissue
Surgical face wound
Open ankle fracture
Traumatic foot wound
Breast tissue
Abscess, unknown site
Arm bone tissue

Texas
Texas
Texas
Texas
Texas
Texas
Florida
South Carolina
Australia
Louisiana
Texas
Missouri
Florida
Florida

Surgical wound infection
Cellulitis, osteomyelitis, inguinal lymphadenitis
Septic arthritis
Surgical wound infection, abdominal wall abscess
Cellulitis
Surgical wound infection
Cellulitis
Cellulitis, osteomyelitis
Cellulitis
Surgical wound infection
Cellulitis
Unknown
Unknown
Unknown

Oklahoma
Arkansas
Florida
Florida
Texas
Alabama
Florida
Florida
Texas
North Carolina
Texas
Texas
Unknown
North Carolina

Osteomyelitis, wound infection
Unknown
Osteomyelitis, cellulitis
Unknown
Infected implant
Cellulitis
Cellulitis
Cystic lesion
Surgical wound infection
Cellulitis, osteomyelitis
Osteomyelitis, cellulitis
Unknown
Unknown
Osteomyelitis, cellulitis

Inguinal node

Texas

Lymphadenitis

Environmental
Mf-1615
Mf-1616

Water softener
Water softener

Texas
Texas

None
None

Other
Mf-2100

Urine

Texas

Unknown

Unknown
Mf-2107

Unknown

Unknown

Unknown

Wound related
Mf-114
Mf-147
Mf-182
Mf-205
Mf-388
Mf-443
Mf-450
Mf-485
Mf-611
ATCC 49939 (Mf-661)
Mf-809
Mf-1363
Mf-1411
Mf-1472
Mf-1476
Mf-1533
Mf-1561
Mf-1568
Mf-1691
Mf-1719
Mf-1746
Mf-1824
Mf-1965
Mf-1966
Mf-1997
Mf-2083
Mf-2106
Mf-2121
Lymph node related
ATCC BAA-328 (Mf-771)
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Respiratory
Mf-91
Mf-131
Mf-239
Mf-487
Mf-607
Mf-2075
Mf-2084
Mf-2108
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TABLE 2. Laboratory features of clinical and reference isolates of the selected PRA group of the M. fortuitum D-sorbitol-negative
third biovariant complex and the ATCC type strain of M. porcinum
Isolate group and feature

Random isolates
Arylsulfatase activity (3 days)
Semiquantitative catalase (ⱖ100 mm)a
Catalase (68°C)a
Nitrate reductiona
Iron uptakea
MacConkey agar
Disk inhibition
Cephalothin (diameter of inhibition, ⬎6 mm)a

ATCC BAA-328

ATCC 49939

Clinical isolates (no.
positive/no. tested) (%)

⫺/⫺
⫹

⫺/⫺
⫹

⫺/⫺
⫹

0/46 (0)
36/46 (78)

⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹

⫹
⫹
⫹
⫹

46/46 (100)
46/46 (100)
14/46 (30)
46/46 (100)

⫹
⫹
⫺
⫺
⫹
⫺

⫹
⫹
⫺
⫺
⫺
⫺

⫹
⫹
⫺
⫺
⫹
⫺

46/46 (100)
46/46 (100)
0/46 (0)
0/46 (0)
35/46 (76)
0/46 (0)

⫹
⫹

⫹
⫺

⫹
⫹

46/46 (100)
17/46 (37)

⫹
⫺b
⫹
⫺
⫹
ND

⫹
NDc
ND
ND
ND
ND

⫹
⫺
⫹
⫹
⫹
⫹

31/31 (100)
17/17 (100)
14/19 (74)
19/19 (100)
18/19 (95)
17/17 (100)

⫺

⫺

⫺

0/29 (0)

a

First reported data for clinical isolates and for most tests for the ATCC type strain.
b
For M. porcinum ATCC 33776T, the semiquantitative catalase test outcome was weakly positive (the column of bubbles was 65 mm high), a result we considered
negative.
c
ND, not determined.

114); sequevar 4, accession number AY496140 (ATCC 49939); and sequevar 5,
accession number AY496141 (Mf-205). The hsp65 sequence for M. neworleansense ATCC 49404T was submitted to GenBank as AY496143, and the
sequence for M. septicum ATCC 700731T was submitted as AY496142.

RESULTS
Growth and biochemical characteristics. All 48 isolates were
negative for early and late pigmentation, grew at 30°C, grew in
⬍7 days, and were susceptible to polymyxin B. They were
typical of members of the M. fortuitum third biovariant sorbitol-negative group in that all isolates were positive for D-mannitol and i-myo-inositol carbohydrate utilization tests but negative for D-sorbitol (Table 2, All isolates section). Testing of a
small number of isolates was done in 13 additional tests (Table
2, Random isolates section). This showed isolates also to be
typical members of the M. fortuitum complex by virtue of having a positive arylsulfatase reaction at 3 days, growing on MacConkey agar without crystal violet, and being positive for nitrate reduction, iron uptake, and acetamide utilization (Table
2). The isolates were also negative for citrate, L-rhamnose, and
D-trehalose.
These results matched those for M. porcinum ATCC 33776T
except the latter was nitrate negative as previously described
(23). These are the first reported growth and biochemical data
for a number of features (Table 2) for M. porcinum clinical

isolates and for most of these tests for the M. porcinum ATCC
type strain. Some growth and biochemical characteristics for 13
of these strains have been previously reported but were tested
in a different laboratory (16).
␤-Lactamase. ␤-Lactamase IEF patterns showed 9 of 14
(64%) isolates to exhibit ␤-lactamase pattern 2 and 12 of 14
(86%) isolates to exhibit pattern 2 or 4. All isolates with pattern 2 or 4 that were subjected to PRA belonged to this group.
None of the isolates matched ␤-lactamase IEF pattern 3, which
was shown to be present in the M. fortuitum third biovariant
D-sorbitol-negative group in previous studies (28, 32).
FL-HPLC. Four clinical isolates of the selected PRA group
of M. fortuitum third biovariant D-sorbitol-negative isolates
were compared to M. porcinum ATCC 33776T, M. neworleansense ATCC 49404T, M. intracellulare 13950T, M. fortuitum
ATCC 6841T, and M. peregrinum ATCC 14467T. The isolates
of the selected PRA group and M. porcinum yielded mycolic
acid chromatograms that were typical of Mycobacterium species. All produced an indistinguishable pattern of two closely
clustered sets of peaks (Fig. 1). This pattern was indistinguishable from the pattern produced by M. fortuitum, M. peregrinum,
and M. neworleansense. It was separable from the pattern of the
control strain of M. intracellulare (Fig. 1) as well as those of M.
mageritense and members of the M. smegmatis group as reported previously (2, 26).
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All isolates
Pigment (early/late)
Rough colony morphology
Growth at:
⬍7 days
30°C
45°Ca (14 days)
Acetamide
Carbohydrate utilization
D-Mannitol
i-myo-Inositol
D-Glucitol (sorbitol)
L-Rhamnose
D-Trehalose
Citrate
Disk inhibition
Polymyxin B (diameter of inhibition, ⬎6 mm)a
Kanamycin (diameter of inhibition, ⱖ20 mm)a

Third biovariant complex isolates

M. porcinum
ATCC
33776T
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TABLE 3. Susceptibility results for isolates of the selected PRA group of the M. fortuitum sorbitol-negative third biovariant
and M. porcinum ATCC 33776T with the same PRA patterna

Drug

MICs for third biovariant isolates (g/ml)
No. of clinical
third biovariant
isolates tested

Clinical isolates
ATCC 49939

ATCC BAA-328
Range

MIC50

ⱕ2
32
0.5
2
4
8
ⱕ4
2

4, 2
32
0.5, 1
1
8, 16
4
ⱕ1, 2
4

4
32
0.125
1
⬎32
ⱕ0.5
ⱕ1
32

ⱕ1–64
8–64
0.25–1
0.25–4
ⱕ0.12–128
1–8
ⱕ2–8
ⱕ1–⬎32

4
32
0.5
4
16
4
2
16

ND
ND
4

ND
ND
ND

ND
ND
ND

ⱕ0.12–0.25
ⱕ0.25–1
1–8

ⱕ0.12
0.5
4

MIC90

⬎32
32
1
4
⬎32
8
8
32
ⱕ0.12
1
8

Mode

32
32
0.5
4
8, 32
4
ⱕ1
4

39
39
39
39
39
39
39
39

ⱕ0.12
0.25, 0.5
4

16
27
26

a
*, First reported data for clinical isolates and for most drugs for the ATCC reference strains. ND, not determined. MIC50, concentration inhibitory for 50% of
strains. MIC90, concentration inhibitory for 90% of strains.

Susceptibility testing. Drug susceptibility tests using current
NCCLS mycobacterial breakpoints (where available) showed
the clinical isolates to be susceptible to ciprofloxacin, gatifloxacin, levofloxacin, sulfamethoxazole, and linezolid and intermediate or susceptible to cefoxitin, clarithromycin, imipenem, and
amikacin (13). The isolates were intermediate or resistant to
doxycycline except for 1 (2.6%) of 39 strains tested which was
susceptible. The eight drugs tested against all 39 clinical isolates and the two reference isolates are shown in the Group I
section of Table 3, while the three drugs tested against only a
small number of isolates are shown in the Group II section of
Table 3. The M. porcinum type strain, ATCC 33776, gave the
same susceptibility pattern (Table 3). Susceptibilities to amikacin, ciprofloxacin, imipenem, doxycycline, and sulfamethoxazole for 13 of these isolates (Mf-91, Mf-131, Mf-147, Mf-239,
Mf-450, Mf-485, Mf-487, Mf-533, Mf-607, Mf-611, Mf-661, Mf771, and Mf-809) (determined in another laboratory) were
published previously as part of an earlier taxonomy study (16).
These are the first reported susceptibility data for seven antimicrobial agents for M. porcinum (Table 3), including the
ATCC type strain, 33776.
PRA. By PRA of the hsp65 gene, M. porcinum ATCC 33776T
and 49 of the 70 isolates of the third biovariant D-sorbitolnegative group exhibited the same restriction fragment length
polymorphism pattern. They gave fragments of 235 and 210 bp
with BstEII and 140, 125, and 100 bp with HaeIII. This pattern
was unique from those of other currently recognized members
of the M. fortuitum group (Fig. 2), with the exception of M.
septicum. Enzyme restriction using BsaHI, however, distinguished the third biovariant isolates and the M. porcinum reference strain (260-, 100-, and 80-bp fragments) from M. septicum (260- and 80-bp fragments). Twenty-four of the clinical
isolates were subjected to BsaHI digestion, and all gave the
260-, 100-, and 80-bp fragments of M. porcinum. PRA results of
two ATCC isolates and two clinical isolates (ATCC 49939,
ATCC BAA-328, Mf-131, and Mf-487) and M. porcinum ATCC
33776T have been reported previously (16).

16S rRNA gene sequencing. Seventeen (37%) of the 46
clinical isolates (Mf-91, Mf-114, Mf-115, Mf-131, Mf-147, Mf205, Mf-388, Mf-533, Mf-771, Mf-1568, Mf-1615, Mf-1847, Mf1965, Mf-2106, Mf-2107, Mf-2108, and ATCC 49939) among
the third biovariant D-sorbitol-negative group of isolates with
the M. porcinum PRA pattern underwent partial 16S rRNA
gene sequencing, and all exhibited 16S rRNA gene sequences
identical to that of M. porcinum ATCC 33776T over the first
500 bp beginning at the 5⬘ end. This region of the gene also
shows 100% identity with M. neworleansense ATCC 49404T
(presently not included in the MicroSeq database), and therefore 12 clinical isolates (Mf-91, Mf-114, Mf-115, Mf-131, Mf147, Mf-205, Mf-388, Mf-661, Mf-771 Mf-1568, Mf-1615, and
Mf-2190) and ATCC 49939 were subjected to near-complete

FIG. 1. Results of FL-HPLC with two strains of M. porcinum and
three reference strains. The patterns of the last four isolates (B to D)
are considered indistinguishable. (A) M. intracellulare ATCC 13950T;
(B) M. porcinum ATCC 33776T; (C) M. porcinum ATCC 49939; (D) M.
peregrinum type I ATCC 14467T; (E) M. fortuitum ATCC 6841T.
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periods)
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Clarithromycin*
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Gatifloxacin*
Levofloxacin*
Linezolid*

MIC for
M. porcinum
ATCC
33776T
(g/ml)
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sequencing (1,463 bp) of the 16S rRNA gene and compared
with the sequences previously determined for M. neworleansense ATCC 49404T and M. porcinum ATCC 33776T and
ATCC 33775 (25). Ten of the 12 clinical third biovariant isolates and the reference isolates of M. porcinum had 100%
sequence identity to each other, while one clinical strain (Mf2190) differed by 1 bp from the other strains at Escherichia coli
base-pair position 187. One isolate revealed a 1-bp variation
from M. neworleansense at E. coli base-pair position 1135.
hsp65 gene partial sequencing. Twelve of the clinical M.
fortuitum third biovariant D-sorbitol-negative isolates and both
reference strains of M. porcinum were subjected to sequencing
of the 441-bp Telenti fragment (hsp65 gene). Four distinct
sequence variants (sequevars) were observed among the clinical isolates, varying from each other by 1 to 2 bases. Both
ATCC strains of M. porcinum were identical to each other and
showed 2- to 3-bp variations from the clinical strains. The four
clinical sequevars all contained a T3C substitution at positions 246 and 285 that was not present in the two porcine
strains. None of these variations were in regions affected by
restriction enzyme sites for BstEII, HaeIII, or BsaHI. The
hsp65 sequences of M. septicum ATCC 700731T (with a PRA
profile identical to that of M. porcinum as determined by use of
BstEII and HaeIII) and M. neworleansense ATCC 49404T
(identical in the first 500 bp to the 16S rRNA gene sequence
from M. porcinum) were also determined for comparison (Fig.
3). M. neworleansense differed by 11 bp, and M. septicum differed by 6 bp from the M. porcinum reference strains. Interestingly, both of these species also had the T3C substitution at
positions 246 and 285.
DISCUSSION
These studies identified only a few minor phenotypic, drug
susceptibility-related, or molecular differences between the human PRA group of the M. fortuitum third biovariant complex

D-sorbitol-negative group and the porcine reference strains of
M. porcinum. The original 10 strains of M. porcinum, characterized by Tsukamura et al., were found to be nitrate negative
(23). The M. porcinum type strain was negative for nitrate
reduction on repeat testing in the present study, while all third
biovariant D-sorbitol-negative isolates tested, including the two
ATCC strains, were positive for nitrate reduction (20 of 20
isolates; Tsukamura also tested 12 of these isolates in his laboratory, and all were positive). The type strain of M. porcinum
had a low semiquantitative catalase (65 mm), while 17 of the 17
third biovariant isolates had a high (⬎100 mm) semiquantitative catalase. A small number of the third biovariant isolates
were tested for benzoate as a sole carbon source in Tsukamura’s laboratory, with 4 of 12 (33%) being positive compared to
100% positivity of the original published strains of M. porcinum (data not presented) (23). Other studies including drug
susceptibilities, FL-HPLC, PRA, and carbohydrate utilization
gave comparable results for the two groups.
The 16S rRNA gene sequence of the M. fortuitum third
biovariant D-sorbitol-negative strain ATCC 49404 was first reported by Kirschner et al. in 1992 (11). This group subsequently sequenced hypervariable region A of the 16S rRNA
gene of three additional third biovariant D-sorbitol-negative
strains (ATCC 49935, ATCC 49937, and ATCC 49939) and
found them identical to ATCC 49404 (19).
ATCC 49404 was found to have a PRA pattern of the hsp65
gene that differed from those of the other third biovariant
D-sorbitol-negative strains (20), although Turenne et al. recently showed M. porcinum ATCC 33776T to differ from this
strain by only 1 bp over the entire 1,400-bp 16S rRNA gene
sequence (25). Schinsky et al. showed ATCC 49404 to have
DNA-DNA homologies of ⬍50% with all other taxa within the
third biovariant group including M. porcinum and named this
isolate M. neworleansense (16). No other third biovariant Dsorbitol-negative clinical strains were sequenced in the study by
Turenne et al. (25). That group did complete sequences of
other M. fortuitum group members, including M. porcinum
ATCC 33776T, and showed that the latter differed by 8 bp from
its closest sequences. These were M. farcinogenes (a nonpigmented slow grower originally reported by Chamoiseau) (5,
15) and the proposed type strain of M. houstonense, ATCC
49403 (formerly of the M. fortuitum third biovariant D-sorbitolpositive group) (11, 16). Some of those differences are present
in the first 500 bp of the 16S rRNA gene, and this sequence is
presently different from those of all other recognized species.
Of the isolates of the M. fortuitum third biovariant D-sorbitol-negative group whose hsp65 PRA patterns matched that of
M. porcinum ATCC 33776T, 4 isolates in the Schinsky et al.
study (16) and 17 in the present study gave partial 16S rDNA
gene sequences that matched that of the M. porcinum type
strain. Eleven clinical isolates with almost complete 16S rRNA
gene sequencing also showed 100% identity. This suggests that
hsp65 PRA will accurately identify isolates of M. porcinum.
The phenotype, drug susceptibility, and hsp65 gene sequence similarity, the 16S rDNA identity, and the high degree
of overall DNA homology (presented in the study by Schinsky
et al.) (16) provide convincing evidence that the nonpigmented
pig pathogen described in 1983 by Tsukamura et al. (23) is the
same species as the present human pathogen previously
grouped within the M. fortuitum third biovariant D-sorbitol-
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FIG. 2. PRA schema of the 441-bp Telenti fragment of the hsp65
gene for separating members of the M. fortuitum group. An ATCC
reference strain, where applicable, is included.
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negative group (27). We would agree with calling these isolates
M. porcinum, with three reference strains (one porcine, two
human) presently catalogued in the ATCC.
The sources and clinical disease associated with these isolates of M. porcinum clearly define them as human pathogens.
Their role in causing chronic lung infection is not well established, but there is little question of their ability to cause
posttraumatic or postsurgical wound infections, osteomyelitis,
and catheter-related infections. These findings are similar to
what has been reported for all members of the M. fortuitum
third biovariant group (27). As has been noted with several
types of surgical wound infections, the M. porcinum clinical
isolates submitted to us are concentrated among southern
coastal states (6, 12, 29, 30).
This study identified two environmental isolates of M. porcinum (Mf-1615 and Mf-1616), the first of these to be reported.

Both were recovered from tap water (8). This reservoir could
explain the frequent association of this species with catheterrelated infections, since catheter exposure to tap water probably occurs frequently.
M. porcinum isolates are phenotypically separable from isolates of the three recognized or proposed species of the
M. fortuitum third biovariant D-sorbitol-positive group using
L-rhamnose (M. mageritense), D-sorbitol (M. mageritense, M.
houstonense, and M. brisbanense), and clarithromycin susceptibility (same three species) (Table 4). It is not phenotypically
separable from any of the other four presently recognized
species or species of the M. fortuitum third biovariant D-sorbitol-negative group (M. septicum, M. neworleansense, M. concordense, and M. boenickei) (Table 4). All four species have the
same antibiotic susceptibility pattern, including being intermediate or susceptible to cefoxitin and clarithromycin. This com-
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FIG. 3. Alignment of the partial hsp65 gene of the various sequevars of the M. porcinum group and the closely related M. septicum ATCC
700731T and M. neworleansense ATCC 49404T. Base positions represent numbering for the 441-bp Telenti fragment. Regions not shown contain
no variations. M. porcinum sequevar (sqv) 1, M. porcinum ATCC 33776T and M. porcinum ATCC 33775; M. porcinum sqv 2, clinical strains Mf-2190,
Mf-131, Mf-147, Mf-388, Mf-115, ATCC BAA-328 (Mf-771), Mf-1568, and Mf-91; M. porcinum sqv 3, Mf-1615 and Mf-114; M. porcinum sqv 4,
ATCC 49939; M. porcinum sqv 5, Mf-205.
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TABLE 4. Useful tests for separating M. porcinum from other members of the M. fortuitum groupd
Antibiotic resistance
Species (strain)
(reference)

Unique 16S r-DNA

Clari (MIC,
⬎4 g/ml)

Fox (MIC,
ⱖ128 g/
ml)

D-man

i-myo-inos

D-sorb

Lrham

Low
catalase
(⬍100
mm)

Var

⫺

⫺

⫺

⫺

⫺

⫺

⫹

⫹

⫹

⫹

⫺

⫺

⫹

⫹

⫺

⫺

⫺

⫺

⫺a

⫺

⫹

⫹

⫺

⫹

⫹

⫹

⫹

⫹

⫹

⫹

⫹

⫹

⫺

⫺

⫹

⫹

⫺

⫺

⫺

⫹

⫺a

⫺

⫹

⫺

⫺

⫹

⫹

⫺

⫺

⫺

⫹

⫺a,b

⫺b

⫺b

⫹

⫹

⫹

⫹

⫹

⫺

⫹

⫺

⫺c

⫺c

⫺c

⫺

⫺

⫹

⫹

⫺

⫺

⫺

⫹

⫺a

NK

⫹

⫺

⫺

⫹

⫺

⫺

⫺

⫺

⫹

⫺b

⫺b

⫺b

⫺

⫺

⫹

⫺

⫺

⫺

⫺

⫹

⫺c

⫺c

⫹

Unique
PRA
hsp65
gene

Hyper-variable
A region

First 500
bp (5⬘
end)

Entire
sequence

a

M. porcinum and other members of the M. fortuitum third biovariant sorbitol-negative group, other than M. septicum, have the same hypervariable A sequence.
M. septicum and M. peregrinum type I have the same sequence over the entire 1,400-bp 16S rRNA gene sequence.
M. senegalense, M. houstonense, and M. farcinogenes have the same sequence over the first 500 bp. M. houstonense and M. farcinogenes are also identical over the
entire 1,400 bp.
d
An ATCC reference strain, where applicable, is included. Abbreviations: Var, variable; Clari, clarithromycin; Fox, cefoxitin; man, mannitol; inos, inositol; sorb,
sorbitol (D-glucitol); rham, rhamnose; ⫹, ⱖ90% positive for indicated characteristic; ⫺, ⱕ10% negative for indicated characteristic; NK, not known.
b
c

ment is qualified by the observation that only a single strain
each of M. septicum, M. neworleansense, and M. concordense
has been reported and characterized to date (16, 17).
The best biochemical screening test for selection of M. fortuitum among isolates belonging to the M. fortuitum group
would appear to be D-mannitol. D-Mannitol-negative isolates
are presumptive M. fortuitum, while D-mannitol-positive isolates are not M. fortuitum but require additional testing to
define the species. Sequencing of the hypervariable A region of
the 16S rRNA gene or even the first 500 bp results in a great
deal of overlap for numerous taxa (25). This region identifies
M. porcinum and M. neworleansense as distinct from the rest of
the M. fortuitum complex but identical to each other. A single
additional sequencing reaction encompassing the V7 region of
the 16S rRNA gene can differentiate between these two species
due to a 1-bp variation at position 1135 and could therefore
provide accurate species identification. These species are better distinguished by their hsp65 sequences, showing 11 mismatches or a 97.5% sequence identity, contributing to clearly
distinct PRA patterns. The best single molecular test for identifying species within the M. fortuitum group would appear to
be hsp65 PRA, as it clearly separated the sorbitol-positive
species and M. boenickei from M. porcinum within the sorbitolnegative group.
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Onyi, E. C. Böttger, and R. J. Wallace, Jr. 1999. Mycobacterium wolinskyi sp.
nov. and Mycobacterium goodii sp. nov., two new rapidly growing species
related to Mycobacterium smegmatis and associated with human wound infections: a cooperative study from the International Working Group on
Mycobacterial Taxonomy. Int. J. Syst. Bacteriol. 49:1493–1511.
3. Brown, B. A., J. M. Swenson, and R. J. Wallace, Jr. 1992. Broth microdilution MIC test for rapidly growing mycobacteria, p. 5.11.1. In H. D. Isenberg
(ed.), Clinical microbiology procedures handbook. American Society for
Microbiology, Washington, D.C.
4. Brown, B. A., R. J. Wallace, Jr., G. Onyi, V. DeRosas, and R. J. Wallace III.
1992. Activities of four macrolides including clarithromycin against Mycobacterium fortuitum, Mycobacterium chelonae, and Mycobacterium chelonaelike organisms. Antimicrob. Agents Chemother. 36:180–184.
5. Chamoiseau, G. 1979. Etiology of farcy in African bovines: nomenclature of
the causal organisms Mycobacterium farcinogenes Chamoiseau and Mycobacterium senegalense (Chamoiseau) comb. nov. Int. J. Syst. Bacteriol. 29:407–
410.
6. Clegg, H. W., M. T. Foster, W. E. Sanders, Jr., and W. B. Baine. 1983.
Infection due to organisms of the Mycobacterium fortuitum complex after

Downloaded from http://jcm.asm.org/ on March 30, 2014 by Washington University in St. Louis

M. fortuitum
(ATCC 6841T)
(4)
M. neworleansense
(ATCC 49404T)
(16, 27)
M. mageritense
(ATCC
700351T) (26)
M. porcinum
(ATCC 33776T,
BAA-328,
ATCC 49939)
M. septicum
(ATCC
700731T) (17)
M. houstonense
(ATCC 49403T)
(4, 16, 27)
M. boenickei
(ATCC 49935T)
(16)
M. peregrinum type
I (ATCC
14467T) (4)
M. senegalense
(ATCC 35796T)

Carbohydrate utilization

FEATURES OF MYCOBACTERIUM PORCINUM

VOL. 42, 2004

7.

8.

9.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.
22.

23.
24.
25.
26.

27.

28.
29.

30.

31.

32.

sequencing of the 16S rRNA gene and proposal of Mycobacterium mucogenicum sp. nov. Int. J. Syst. Bacteriol. 45:262–267.
Steingrube, V. A., J. L. Gibson, B. A. Brown, Y. Zhang, R. W. Wilson, M.
Rajagopalan, and R. J. Wallace, Jr. 1995. PCR amplification and restriction
endonuclease analysis of a 65-kilodalton heat shock protein gene sequence
for taxonomic separation of rapidly growing mycobacteria. J. Clin. Microbiol.
33:149–153.
Swenson, J. M., C. Thornsberry, and V. A. Silcox. 1982. Rapidly growing
mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth
microdilution. Antimicrob. Agents Chemother. 22:186–192.
Telenti, A., F. Marchesi, M. Balz, F. Bally, E. C. Böttger, and T. Bodmer.
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